Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

ASCO 2012 Lung Cancer Highlights: Question and Answer Session with Drs. Socinski and Neal
Dr West
Author
Howard (Jack) West, MD

We've covered a wide range of topics  in our "ASCO 2012 Lung Cancer Highlights" podcast series over the last few weeks.  This webinar and the podcasts from it featured Drs. Mark Socinski from the University of Pittsburgh and Joel Neal from Stanford Cancer Center; following their presentations, they did a question and answer session together, covering a wide range of leading topics in lung cancer from ASCO.  Here's that Q&A session.

ASCO 2012 LC Highlights QA Session Audio Podcast

ASCO 2012 LC Highlights QA Session Transcript

ASCO 2012 LC Highlights QA Session Figs

That's the end of this series, and we again thank LUNGevity Foundation for partnering with us to make it possible. I hope you found it valuable.  If there was a favorite topic, or one that didn't get a mention that you hoped would, please let us know with a comment.

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Recent Comments

JOIN THE CONVERSATION
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on
Biomarkers
By JanineT GRACE … on